10x Genomics (TXG) - What Are Brokerages Thinking About This Stock?

Key Points

• Analysts are broadly neutral: 18 firms give 10x Genomics a consensus “Hold” rating—12 holds, five buys and one sell—with an average 12-month price target of $68.
• Quarterly results beat expectations: 10x reported a loss of $0.15 per share and revenue of $150.7 million, outperforming estimates, but year-over-year revenue growth was just 1.1% and the company remained unprofitable.
• The stock fell sharply despite the earnings beat: Shares were reported down 14%, with modest growth and continuing losses cited as possible reasons investors were unimpressed.

10x Genomics (NASDAQ:TXG - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eighteen ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $68.00.

A number of equities research analysts have weighed in on the company. Barclays lifted their target price on 10x Genomics from $52.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Stifel Nicolaus set a $70.00 target price on shares of 10x Genomics in a research report on Tuesday, October 13th. TD Cowen boosted their price objective on 10x Genomics from $47.00 to $70.00 and gave the company a "hold" rating in a research note on Tuesday, October 13th. Canaccord Genuity Group boosted their price objective on 10x Genomics from $60.00 to $100.00 and gave the company a "buy" rating in a research note on Monday, October 12th. Finally, Citigroup upped their price objective on shares of 10x Genomics from $45.00 to $50.00 and gave the company a "neutral" rating in a report on Friday, August 7th.

Insider Transactions at 10x Genomics

In other news, Director John Stuelpnagel sold 20,000 shares of the firm's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total transaction of $1,235,000.00. Following the sale, the director owned 328,436 shares in the company, valued at approximately $20,280,923. This trade represents a 5.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Benjamin Hindson sold 13,818 shares of the business's stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $63.02, for a total value of $870,810.36. Following the completion of the sale, the insider owned 488,182 shares of the company's stock, valued at $30,765,229.64. The trade was a 2.75% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 179,333 shares of company stock worth $11,810,070. Company insiders own 8.84% of the company's stock.

Hedge Funds Weigh In On 10x Genomics

Hedge funds have recently modified their holdings of the company. Quantinno Capital Management LP increased its stake in shares of 10x Genomics by 16.0% during the first quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company's stock valued at $114,892,000 after purchasing an additional 744,558 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in 10x Genomics by 34.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company's stock valued at $43,357,000 after buying an additional 525,369 shares during the last quarter. Quantedge Capital Pte Ltd raised its stake in 10x Genomics by 104.2% during the first quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company's stock valued at $8,843,000 after buying an additional 212,600 shares during the last quarter. Hsbc Holdings PLC purchased a new position in 10x Genomics during the first quarter valued at $5,945,000. Finally, Swiss National Bank boosted its holdings in 10x Genomics by 2.2% in the first quarter. Swiss National Bank now owns 207,400 shares of the company's stock worth $4,403,000 after acquiring an additional 4,400 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

10x Genomics Trading Down 14.0%

10x Genomics stock opened at $58.06 on Friday. 10x Genomics has a 12 month low of $12.80 and a 12 month high of $102.81. The stock has a 50-day moving average price of $74.06 and a two-hundred day moving average price of $41.41. The company has a market capitalization of $7.56 billion, a PE ratio of -98.41 and a beta of 2.03.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.12. The firm had revenue of $150.67 million during the quarter, compared to the consensus estimate of $147.96 million. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The company's revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.22) earnings per share. As a group, analysts predict that 10x Genomics will post -0.77 earnings per share for the current fiscal year.

Key Headlines Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q3 revenue was $150.7 million, above the roughly $148 million consensus, while the loss of $0.15 per share was narrower than analysts’ expected loss of $0.27. Revenue increased 1.1% year over year. Article: 10x Genomics Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: The company forecast 2026 revenue of $625 million to $635 million and said it is targeting about 50 Atera shipments by year-end, providing a revenue outlook and a near-term product milestone. Article: 10x Genomics Forecasts 2026 Revenue and Atera Shipments
• Neutral Sentiment: Broader technology stocks were volatile, with a report noting a sharp Nasdaq decline followed by a bounce. That market backdrop may have added uncertainty, but the article does not identify a TXG-specific effect. Article: Dow Jones Futures Fall, Techs Bounce
• Negative Sentiment: Despite the earnings beats, TXG declined after the results. The quarter still showed only 1.1% year-over-year revenue growth and a net loss, which may have tempered investor enthusiasm. Article: Q3 Sales Top Estimates but Stock Drops

10x Genomics Company Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company's product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.